#3

THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of

Johe IKEDA et al.

Serial No. 09/830,338

Attn: BOX PCT

Filed April 26, 2001

Attorney Docket No. 2001-0515A

MONOCLONAL ANTIBODIES AGAINST HUMAN APOPTOSIS INHIBITORY PROTEIN NAIP AND METHOD FOR ASSAYING THE NAIP

PATENT OFFICE FEE TRANSMITTAL FORM

Assistant Commissioner for Patents, Washington, DC 20231

Sir:

THE COMMISSIONER IS AUTHORIZED TO CHARGE ANY DEFICIENCY IN THE FEE FOR THIS PAPER TO DEPOSIT ACCOUNT NO. 23-0975.

Attached hereto is a check in the amount of \$130.00 to cover Patent Office fees relating to filing the following attached papers:

A duplicate copy of this paper is being submitted for use in the Accounting Division, Office of Finance.

The Commissioner is authorized to charge any deficiency or to credit any overpayment associated with this communication to Deposit Account No. 23-0975, with the EXCEPTION of deficiencies in fees for multiple dependent claims in new applications.

Respectfully submitted,

07/17/2001 HNGUYEN 00000022 09830338

Johe IKEDA et al.

01 FC:154

130.00 OP

By

Warren M. Cheek, Jr. Registration No. 33,367 Attorney for Applicants

Natucheele

WMC/jlw WENDEROTH, LIND & PONACK, L.L.P. 2033 K St., N.W., Suite 800 Washington, D.C. 20006-1021 Telephone (202) 721-8200 July 11, 2001

[Check No. <u>45393</u>

2001_0515A

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of

Johe IKEDA et al.

Serial No. 09/830,338

Filed April 26, 2001

JUL 1:1 2001

Attn: BOX PCT

Docket No. 2001 0515A

MONOCLONAL ANTIBODIES AGAINST **HUMAN APOPTOSIS INHIBITORY PROTEIN** NAIP AND METHOD FOR ASSAYING THE NAIP [Corresponding to PCT/JP99/05841 Filed October 22, 1999]

THE COMMISSIONER IS AUTHORIZED TO CHARGE ANY DEFICIENCY IN THE FEE FOR THIS PAPER TO DEPOSIT ACCOUNT NO. 23-0975.

REPLY TO NOTIFICATION OF MISSING REQUIREMENTS **UNDER 35 USC 371**

Assistant Commissioner for Patents, Washington, DC 20231

Sir:

In response to the PTO Notification of Missing Requirements Under 35 USC 371 dated June 12, 2001, submitted herewith is a Declaration for the above application executed by the inventors.

Also enclosed are the PTO surcharge of \$130.00 required by 37 CFR 1.492(e), and a copy of the PTO notice.

It is respectfully submitted that the application is now complete, and early indication thereof is now requested.

Respectfully submitted,

Johe IKEDA et al.

Registration No. 33,367

Attorney for Applicants

WMC/ilw Washington, D.C. 20006-1021 Telephone (202) 721-8200 Facsimile (202) 721-8250 July 11, 2001

17 Rec'd PCT/PTO

1 1 JUL 2001



HE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of

Johe IKEDA et al.

Serial No. 09/830,338

Attn: BOX PCT

Filed April 26, 2001

Attorney Docket No. 2001-0515A

MONOCLONAL ANTIBODIES AGAINST HUMAN APOPTOSIS INHIBITORY PROTEIN NAIP AND METHOD FOR ASSAYING THE NAIP

PATENT OFFICE FEE TRANSMITTAL FORM

Assistant Commissioner for Patents, Washington, DC 20231

Sir:

THE COMMISSIONER IS AUTHORIZE TO CHARGE AND DEFICIENCY IN T. F. FEE FOR THIS PAPER IC DEBUSIN ACCOUNT NO. 23-0975.

Attached hereto is a check in the amount of \$130.00 to cover Patent Office fees relating to filing the following attached papers:

A duplicate copy of this paper is being submitted for use in the Accounting Division, Office of Finance.

The Commissioner is authorized to charge any deficiency or to credit any overpayment associated with this communication to Deposit Account No. 23-0975, with the EXCEPTION of deficiencies in fees for multiple dependent claims in new applications.

Respectfully submitted,

Johe IKEDA et al.

Warren M. Cheek, Jr.

Registration No. 33,367 Attorney for Applicants

WMC/ilw WENDEROTH, LIND & PONACK, L.L.P. 2033 K St., N.W., Suite 800 Washington, D.C. 20006-1021 Telephone (202) 721-8200 July 11, 2001

[Check No. 45392

2001 0515A

Commissioner for Patents, Box PCT United States Patent and Trademark Office Washington, D.C. 20231 www.usplo.gov

TO STATES UN LAND				www.usplo gov
U.S. APPLICATION NO		FIRST NAMED APP	LICANF.	ATTY DOCKET NO
09/83033	38	IKEDA	J	2001-0515A
		•	INTERNATION	AL APPLICATION NO
WENDEROTH, LIN	ND & PONACK, L.L.P.		PCTA	JP99/05841
2033 K STREET N	i. W .		٠	
SUITE 800 WASHINGTON, DO	C 20006 1021		LA. FILING DATE	PRIORITY DATE
			22 OCT 99	26 OCT 98
!				10 1111 2001
				12 JUN 2001
NOTIFICATIO			UNDER 35 U.S.C. 371	
1			D OFFICE (DO/EO/US	
			to the United States Patent and ted Office (37 CFR 1.495):	1 Frademark
	ic National Fee.	· ·	Small Entity Status.	MEGEIWE
ات	he international application		f the international application i	nto English.
Oath or D	Declaration of inventors(s)). Translation o	of Article 19 amendments into I	English 4 Unit 1 3 Occ.
'	Article 19 amendments.	Other:		JUN 13 2001
Priority D		anticulture Disease to Paul		
			ish and its Annexes, if any. :amination Report into English.	WENDEROTH, LIND & PONAC
	ar or minexes to the me.	macional i terminary DA	annuation report into English.	
2. Applicant has re	equested early processing	under 35 U.S.C. 371(f)	but has not filed the following	indicated items and/or
			the copy of the international ar	oplication must be filed
	hs from the priority date ic National Fee.		nternational application.	
		[
		ithin the period set forth	below in order to complete the	requirements for
acceptance under 35 U		to English. A processin	g fee will be required if submi	tted
	than the appropriate 20			
			dicated on the attached Notice	of Defective
	nslation.	translation of the applic	cation and/or the Annexes later	thun the
	copriate 20 or 30 months			, ·
			37 CFR 1.497(a) and (b), pro	perly identifying
			ation number and international	
surci date.	-	submitted fater than the	appropriate 20 or 30 months fr	on the priority
The	current oath or declaration	on does not comply with	37 CFR 1.497(a) and (b) for t	he wasons
	cated on the attached PCT		in the appropriate 20 or 30 mor	athe from the
	rity date (37 CFR 1.492)		in the appropriate 20 or 30 mor	ans nom the
4. Additional claim fe	ecs of \$as	a large entity sm	all entity, including any requir	
			s or cancel the additional clain	is for which fees are
due (37 CFR 1.492(g))). See attached PTO-875	J.•		
	ot submitted the required	sequence listing pursuar	nt to 37 CFR 1.821-1.825. Se	e attached
PCT/DO/EO/920.				
			MUST BE SUBMITTED W	
			2 MONTHS (where 37 CFR R IS LATER. FAILURE TO	
	ESULT IN ABANDONN			
The sales of the sales		Milian a marking and Co.	for artangian of time and - the	provisions of 27 CUD
The time period set about 1.136(a).	ove may be extended by	tining a petition and fee	for extension of time under the	provisions or 57 CPK
			ubmitted no later than the time ted later than 20 or 30 months	
			not provided by the appropria	

Applicant is reminded that any communication to the United States Patent and Trademark Office must be mailed to the address given in the heading and include the U.S. application no. st own above. (37 CFR 1.5)

	A copy of this notice MUST be returned with this response.						
Enclosed:	PCT/DO/EO/917	Notice of Defective PCT/DO/EO/920	Translation John Anderson	JAN			
FORM PCT/DO/EO/905 (March 2001)			Telephone: 703 308-9116	/			

or $\overline{30}$ (37 CFR 1.495(d)) months from the priority date.